



Non-coding RNA in Hematological Cancers

Guest Editor:

Dr. Srinivas V Koduru

Department of Cellular and
Molecular Physiology, Penn State
College of Medicine, Hershey, PA
17033, USA

Deadline for manuscript
submissions:

closed (1 February 2021)

Message from the Guest Editor

This Special Issue covers all types of non-coding RNAs in hematological cancers. Small RNAs consist of 17–250 nucleotides in length; among them, microRNAs (miRNAs) are the most studied and well known non-coding RNAs. Piwi-interacting RNAs (piRNAs) are the largest class of the small non-coding RNA family and are implicated in epigenetic and post-transcriptional regulation but still lack functional characterization. Long non-coding RNAs (lncRNAs) are a diverse class of RNAs, believed to play an important role in cellular mechanisms; however, little biological relevance has been established thus far. Circular RNAs (circRNAs) are a recently rediscovered RNA class of non-coding RNAs. Small nuclear/nucleolar RNAs (sn/snoRNAs) are perhaps the most ancient and highly conserved class of sncRNAs, carrying out a fundamental role in the modification and processing of ribosomal RNAs (rRNA), transfer RNAs (tRNA), and small nuclear RNAs (snRNA).





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com